(19)
(11) EP 4 436 998 A1

(12)

(43) Date of publication:
02.10.2024 Bulletin 2024/40

(21) Application number: 22840432.3

(22) Date of filing: 23.11.2022
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2818; C07K 2317/31; C07K 2317/76; A61P 35/00; C07K 2317/92
(86) International application number:
PCT/US2022/050934
(87) International publication number:
WO 2023/097024 (01.06.2023 Gazette 2023/22)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 24.11.2021 US 202163282887 P

(71) Applicant: Dana-Farber Cancer Institute, Inc.
Boston, Massachusetts 02215 (US)

(72) Inventors:
  • MARASCO, Wayne A.
    Wellesley, Massachusetts 02481 (US)
  • CHANG, Matthew
    Brookline, Massachusetts 02135 (US)

(74) Representative: Barker Brettell LLP 
100 Hagley Road Edgbaston
Birmingham B16 8QQ
Birmingham B16 8QQ (GB)

   


(54) ANTIBODIES AGAINST CTLA-4 AND METHODS OF USE THEREOF